Dermorphin vs Pentosan (Joint Pain)
A side-by-side research comparison of Dermorphin and Pentosan (Joint Pain) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Dermorphin | Pentosan (Joint Pain) |
|---|---|---|
| Full name | Dermorphin (Opioid Heptapeptide) | Pentosan Polysulfate Sodium (Cartrophen) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Research compound | FDA Approved (interstitial cystitis) / Veterinary approved |
| Mechanism | Binds mu-opioid receptors with very high affinity and selectivity, producing potent analgesia. Its unusual D-alanine residue makes it resistant to breakdown, contributing to a much stronger effect than morphine on a per-weight basis. | Inhibits matrix metalloproteinases (MMPs) and aggrecanases that degrade cartilage. Stimulates hyaluronic acid production by synoviocytes. Promotes proteoglycan synthesis by chondrocytes. Reduces subchondral bone remodeling via anti-inflammatory effects. |
| Molecular weight | 803.9 Da | ~4000-6000 Da (average) |
| Half-life | Short (peptide) | ~24 hours |
| Bioavailability | Injection (research) | ~6% oral; ~100% subcutaneous |
| Typical dose | Not established for human use | 2-3 mg/kg SC (veterinary extrapolation) or 100mg oral 3x/day |
| Frequency | Research only | Weekly SC injections (4-6 course) or daily oral |
| Route | Injection (research) | Subcutaneous injection or oral capsule |
Dermorphin reported benefits
- Potent analgesia (research context)
- High mu-opioid receptor selectivity (research interest)
Pentosan (Joint Pain) reported benefits
- Cartilage protection and repair
- Reduced joint inflammation
- Improved synovial fluid
- Disease-modifying (not just symptomatic)
- Reduced bone marrow edema
- Alternative to corticosteroid injections
Related comparisons
Research and educational reference only. Not medical advice.